Journal of labelled compounds and radiopharmaceuticals p. 829 - 843 (2005)
Update date:2022-08-03
Topics:
Seimbille, Yann
Phelps, Michael E.
Czernin, Johannes
Silverman, Daniel H. S.
Inhibitors of tyrosine kinase enzymatic activity represent a promising new class of antineoplastic agents. Although clinical studies performed over the last decade give more insight on the potential therapeutic applications of such drugs, identification of the individual patients who might benefit from them remains a major challenge. We have developed a synthetic strategy for the production of a wide variety of radiolabeled 6,7-disubstituted 4-anilinoquinazolines suitable for noninvasive imaging of tyrosine kinase receptors to predict therapy effectiveness. Three new F-18 labeled radiopharmaceuticals based on the therapeutic agents Tarceva, Iressa, and ZD6474 were synthesized. Decay-corrected yields varied between 25 and 40% for a total synthesis time of 120 min, thus providing F-18 labeled tyrosine kinase inhibitors in quantities and times practical for use as PET radiopharmaceuticals. Copyright
View MoreHubei Danao Pharmaceutical Co.,Ltd.
website:http://www.danaopharm.com
Contact:+86-719-5251167
Address:Fandan Road,Danjiangkou,Hubei
Jinhua Haoyuan Chemical CO., LTD
Contact:86-579-82465583
Address:Jinhua,Zhejiang
Contact:0571-86821378 ,86820258,56836287,56830923,
Address:Block D ,20F, Tianyuan Building,No.508, Wensan RD, 310013,Hangzhou Zhejiang China
Neworld Chemical Co., Ltd Shanghai
Contact:+86-21-62202658
Address:11F, Blvd 2, No. 1969 PuXing Rd, Shanghai
NINGBO YINLIANG FOREIGN TRADE CO., LTD.
Contact:+86-574-87834016 / 87898057
Address:23F NO.666JINYU ROAD,YINGZHOU DISTRICT,NINGBO.CHINA
Doi:10.1021/ic0008969
(2001)Doi:10.1007/BF00929550
(1960)Doi:10.1021/ol2006083
(2011)Doi:10.1016/j.bmcl.2008.09.028
(2008)Doi:10.1021/acs.jmedchem.8b00756
(2018)Doi:10.1039/P29840000615
(1984)